Bladder Cancer - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 937
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B363EFB63CFEN
Leaflet:

Download PDF Leaflet

Bladder Cancer - Pipeline Review, H2 2017
Bladder Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 53, 52, 5, 63, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 2, 10 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Bladder Cancer - Overview
Bladder Cancer - Therapeutics Development
Bladder Cancer - Therapeutics Assessment
Bladder Cancer - Companies Involved in Therapeutics Development
Bladder Cancer - Drug Profiles
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Bladder Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Bladder Cancer - Pipeline by 4SC AG, H2 2017
Bladder Cancer - Pipeline by Abivax SA, H2 2017
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Bladder Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017
Bladder Cancer - Pipeline by Altor BioScience Corp, H2 2017
Bladder Cancer - Pipeline by AndroScience Corp, H2 2017
Bladder Cancer - Pipeline by ANP Technologies Inc, H2 2017
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2017
Bladder Cancer - Pipeline by Archivel Farma SL, H2 2017
Bladder Cancer - Pipeline by Argos Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Arno Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Array BioPharma Inc, H2 2017
Bladder Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Bladder Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H2 2017
Bladder Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by AstraZeneca Plc, H2 2017
Bladder Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Bladder Cancer - Pipeline by Bayer AG, H2 2017
Bladder Cancer - Pipeline by Biocad, H2 2017
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2017
Bladder Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Bladder Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Bladder Cancer - Pipeline by Biotest AG, H2 2017
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Bladder Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Bladder Cancer - Pipeline by Celgene Corp, H2 2017
Bladder Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Celprogen Inc, H2 2017
Bladder Cancer - Pipeline by Celsion Corp, H2 2017
Bladder Cancer - Pipeline by Celyad SA, H2 2017
Bladder Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
Bladder Cancer - Pipeline by Cold Genesys Inc, H2 2017
Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Bladder Cancer - Pipeline by Eisai Co Ltd, H2 2017
Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Eli Lilly and Co, H2 2017
Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2017
Bladder Cancer - Pipeline by EpiThany Inc, H2 2017
Bladder Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Exelixis Inc, H2 2017
Bladder Cancer - Pipeline by Exicure Inc, H2 2017
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Bladder Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2017
Bladder Cancer - Pipeline by Genentech Inc, H2 2017
Bladder Cancer - Pipeline by Genmab A/S, H2 2017
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Bladder Cancer - Pipeline by H3 Biomedicine Inc, H2 2017
Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2017
Bladder Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Bladder Cancer - Pipeline by HitGen LTD, H2 2017
Bladder Cancer - Pipeline by Horizon Pharma Plc, H2 2017
Bladder Cancer - Pipeline by Immunocore Ltd, H2 2017
Bladder Cancer - Pipeline by Immunomedics Inc, H2 2017
Bladder Cancer - Pipeline by Immupharma Plc, H2 2017
Bladder Cancer - Pipeline by Imugene Ltd, H2 2017
Bladder Cancer - Pipeline by Incanthera Ltd, H2 2017
Bladder Cancer - Pipeline by Incyte Corp, H2 2017
Bladder Cancer - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by InteRNA Technologies BV, H2 2017
Bladder Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Johnson & Johnson, H2 2017
Bladder Cancer - Pipeline by Kite Pharma Inc, H2 2017
Bladder Cancer - Pipeline by Laboratoires Pierre Fabre SA, H2 2017
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H2 2017
Bladder Cancer - Pipeline by Loxo Oncology Inc, H2 2017
Bladder Cancer - Pipeline by Lycera Corp, H2 2017
Bladder Cancer - Pipeline by MacroGenics Inc, H2 2017
Bladder Cancer - Pipeline by Marina Biotech Inc, H2 2017
Bladder Cancer - Pipeline by MaxiVAX SA, H2 2017
Bladder Cancer - Pipeline by Medicenna Therapeutics Corp, H2 2017
Bladder Cancer - Pipeline by MedImmune LLC, H2 2017
Bladder Cancer - Pipeline by Merck & Co Inc, H2 2017
Bladder Cancer - Pipeline by Merck KGaA, H2 2017
Bladder Cancer - Pipeline by Mirati Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2017
Bladder Cancer - Pipeline by MTG Biotherapeutics Inc, H2 2017
Bladder Cancer - Pipeline by NanoCarrier Co Ltd, H2 2017
Bladder Cancer - Pipeline by NantKwest Inc, H2 2017
Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2017
Bladder Cancer - Pipeline by Novartis AG, H2 2017
Bladder Cancer - Pipeline by OncoTherapy Science Inc, H2 2017
Bladder Cancer - Pipeline by Oncovir Inc, H2 2017
Bladder Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Bladder Cancer - Pipeline by Optimum Therapeutics LLC, H2 2017
Bladder Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2017
Bladder Cancer - Pipeline by Pfizer Inc, H2 2017
Bladder Cancer - Pipeline by Pharma Mar SA, H2 2017
Bladder Cancer - Pipeline by Philogen SpA, H2 2017
Bladder Cancer - Pipeline by Pieris Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Plexxikon Inc, H2 2017
Bladder Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Provecs Medical GmbH (Inactive), H2 2017
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2017
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Samyang Holdings Corp, H2 2017
Bladder Cancer - Pipeline by Sanofi, H2 2017
Bladder Cancer - Pipeline by Sareum Holdings Plc, H2 2017
Bladder Cancer - Pipeline by Shionogi & Co Ltd, H2 2017
Bladder Cancer - Pipeline by Sierra Oncology Inc, H2 2017
Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2017
Bladder Cancer - Pipeline by Sitka Biopharma Inc, H2 2017
Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Stemline Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Bladder Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2017
Bladder Cancer - Pipeline by Theralase Technologies Inc, H2 2017
Bladder Cancer - Pipeline by Tocagen Inc, H2 2017
Bladder Cancer - Pipeline by Tolero Pharmaceuticals Inc, H2 2017
Bladder Cancer - Pipeline by Transgene SA, H2 2017
Bladder Cancer - Pipeline by UroGen Pharma Ltd, H2 2017
Bladder Cancer - Pipeline by Vaccibody AS, H2 2017
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2017
Bladder Cancer - Pipeline by Vault Pharma Inc, H2 2017
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2017
Bladder Cancer - Pipeline by Vaxiion Therapeutics Inc, H2 2017
Bladder Cancer - Pipeline by Viralytics Ltd, H2 2017
Bladder Cancer - Pipeline by Vyriad Inc, H2 2017
Bladder Cancer - Pipeline by Zymeworks Inc, H2 2017
Bladder Cancer - Dormant Projects, H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.4), H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.5), H2 2017
Bladder Cancer - Dormant Projects, H2 2017 (Contd.6), H2 2017
Bladder Cancer - Discontinued Products, H2 2017
Bladder Cancer - Discontinued Products, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Bladder Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

4SC AG
Abivax SA
Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Altor BioScience Corp
AndroScience Corp
ANP Technologies Inc
APIM Therapeutics AS
Archivel Farma SL
Argos Therapeutics Inc
Arno Therapeutics Inc
Array BioPharma Inc
Asana BioSciences LLC
Asieris Pharmaceuticals Co Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bavarian Nordic A/S
Bayer AG
Biocad
BioCancell Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biomics Biotechnologies Co Ltd
Biotest AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
Celldex Therapeutics Inc
Celprogen Inc
Celsion Corp
Celyad SA
Cleveland BioLabs Inc
Cold Genesys Inc
Corvus Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytori Therapeutics Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Eleven Biotherapeutics Inc
Eli Lilly and Co
Elsalys Biotech SAS
EpiThany Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
Exicure Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Gene Signal International SA
Genentech Inc
Genmab A/S
GlaxoSmithKline Plc
H3 Biomedicine Inc
Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
HitGen LTD
Horizon Pharma Plc
Immunocore Ltd
Immunomedics Inc
Immupharma Plc
Imugene Ltd
Incanthera Ltd
Incyte Corp
Innovation Pharmaceuticals Inc
InteRNA Technologies BV
Iovance Biotherapeutics Inc
Johnson & Johnson
Kite Pharma Inc
Laboratoires Pierre Fabre SA
LipoMedix Pharmaceutical Inc
Loxo Oncology Inc
Lycera Corp
MacroGenics Inc
Marina Biotech Inc
MaxiVAX SA
Medicenna Therapeutics Corp
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Moleculin Biotech Inc
MTG Biotherapeutics Inc
NanoCarrier Co Ltd
NantKwest Inc
Nektar Therapeutics
Novartis AG
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
Pieris Pharmaceuticals Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Provecs Medical GmbH (Inactive)
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Rexahn Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi
Sareum Holdings Plc
Shionogi & Co Ltd
Sierra Oncology Inc
Sillajen Biotherapeutics
Sitka Biopharma Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Taris Biomedical LLC
Theralase Technologies Inc
Tocagen Inc
Tolero Pharmaceuticals Inc
Transgene SA
UroGen Pharma Ltd
Vaccibody AS
Vakzine Projekt Management GmbH
Vault Pharma Inc
Vaxeal Holding SA
Vaxiion Therapeutics Inc
Viralytics Ltd
Vyriad Inc
Zymeworks Inc
Skip to top


Head And Neck Cancer - Pipeline Review, H2 2017 US$ 2,500.00 Oct, 2017 · 1466 pages
Gastric Cancer - Pipeline Review, H2 2017 US$ 2,500.00 Oct, 2017 · 1110 pages

Ask Your Question

Bladder Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: